Business, energy, technology, markets and global industry news from Business News Today

AAD 2026

PharmaDeviceNews AAD 2026
Representative image of a child undergoing a dermatology skin examination, illustrating the growing focus on pediatric eczema treatment as Galderma’s nemolizumab phase II data sharpen competition in the biologic landscape for atopic dermatitis.
Pharma & Biotech

What Galderma’s nemolizumab phase II data mean for the competitive biologic landscape in pediatric eczema

Galderma's nemolizumab phase II data in children aged 2-11 show 52-week itch and lesion relief. Read the analysis.

Read More
Pharma & Biotech

Can Incyte’s 54-week povorcitinib data redefine the oral treatment landscape in hidradenitis suppurativa?

Incyte presents 54-week STOP-HS phase 3 data for povorcitinib at AAD 2026. Analyst review of durability, safety, and what the dataset means for the NDA.

Read More